Transforming mantle cell lymphoma: the journey across eras
In this issue of Haematologica, Jiang et al. report the evolution of overall survival (OS) and failure-free survival (FFS) following front-line therapy for mantle cell lymphoma (MCL) across different eras by pooling data from 6 phase III trials for treatment na 0ve and advanced stage MCL conducted from 1996 to 2020.
The article summarizes how treatment advances over 25 years have progressively improved survival outcomes for patients with mantle cell lymphoma (MCL), a historically incurable disease.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
- Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology
- Refining risk stratification for mantle cell lymphoma: integrating novel combination treatments and personalized approaches.
- Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma
- Hairy Cell Leukemia: Clinical Characteristics and Outcomes from a Single Center in the Middle East and North Africa